Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cancer Chemotherapy and Pharmacology
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2017

26.11.2016 | Review Article

Research progress of hydroxychloroquine and autophagy inhibitors on cancer

verfasst von: Ting-Ting Shi, Xiao-Xu Yu, Li-Jun Yan, Hong-Tao Xiao

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hydroxychloroquine (HCQ), the analog of chloroquine, augments the effect of chemotherapies and radiotherapy on various tumors identified in the current clinical trials. Meanwhile, the toxicity of HCQ retinopathy raises concern worldwide. Thus, the potent autophagy inhibitors are urgently needed.

Methods

A systematic review was related to ‘hydroxychloroquine’ or ‘chloroquine’ with ‘clinical trials,’ ‘retinopathy’ and ‘new autophagy inhibitors.’ This led to many cross-references involving HCQ, and these data have been incorporated into the following study.

Results

Many preclinical studies indicate that the combination of HCQ with chemotherapies or radiotherapies may enhance the effect of anticancer, providing base for launching cancer clinical trials involving HCQ. The new and more sensitive diagnostic techniques report a prevalence of HCQ retinopathy up to 7.5%. Lys05, SAR405, verteporfin, VATG-027, mefloquine and spautin-1 may be potent autophagy inhibitors.

Conclusion

Additional mechanistic studies of HCQ in preclinical models are still required in order to answer these questions whether HCQ actually inhibits autophagy in non-selective tumors and whether the extent of inhibition would be sufficient to alter chemotherapy or radiotherapy sensitivity.
Literatur
1.
Rubinsztein DC, Codogno P, Levine B (2012) Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11:709–730CrossRefPubMedPubMedCentral
2.
3.
4.
5.
Wolf R, Wolf D, Ruocco V (2000) Antimalarials: unapproved uses or indications. Clin Dermatol 18:17–35CrossRefPubMed
6.
7.
Amaravadi RK, Lippincott-Schwartz J, Yin XM et al (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654–666CrossRefPubMedPubMedCentral
8.
Barnard RA, Wittenburg LA, Amaravadi RK et al (2014) Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 10:1415–1425CrossRefPubMedPubMedCentral
9.
Mahalingam D, Mita M, Sarantopoulos J et al (2014) Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10:1403–1414CrossRefPubMedPubMedCentral
10.
Rangwala R, Chang YC, Hu J et al (2014) Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10:1391–1402CrossRefPubMedPubMedCentral
11.
Rangwala R, Leone R, Chang YC et al (2014) Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10:1369–1379CrossRefPubMedPubMedCentral
12.
Rosenfeld MR, Ye X, Supko JG et al (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359–1368CrossRefPubMedPubMedCentral
13.
Vogl DT, Stadtmauer EA, Tan KS et al (2014) Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10:1380–1390CrossRefPubMedPubMedCentral
14.
Wolpin BM, Rubinson DA, Wang X et al (2014) Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 19:637–638CrossRefPubMedPubMedCentral
15.
Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460CrossRefPubMed
16.
Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62:775–784CrossRef
17.
Marmor MF, Kellner U, Lai TY, et al. (2016) American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) [published online March 16, 2016]. Ophthalmology. doi:10.​1016/​j.​ophtha.​2016.​01.​058
18.
19.
20.
Townsend KN et al (2012) Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev 249(1):176–194CrossRefPubMed
21.
22.
23.
Chen M, Hong MJ, Sun H et al (2014) Essential role for autophagy in the maintenance of immunological memory against influenza infection. Nat Med 20:503–510CrossRefPubMedPubMedCentral
24.
Zou CG, Ma YC, Dai LL et al (2014) Autophagy protects C elegans against necrosis during Pseudomonas aeruginosa infection. Proc Natl Acad Sci USA 111:12480–12485CrossRefPubMedPubMedCentral
25.
26.
Rao S, Yang H, Penninger JM et al (2014) Autophagy in non-small cell lung carcinogenesis: a positive regulator of antitumor immunosurveillance. Autophagy 10:529–531CrossRefPubMedPubMedCentral
27.
Wong YC, Holzbaur EL (2014) Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc Natl Acad Sci USA 111:E4439–E4448CrossRefPubMedPubMedCentral
28.
McLendon PM, Ferguson BS, Osinska H et al (2014) Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci USA 111:E5178–E5186CrossRefPubMedPubMedCentral
29.
Morselli E, Galluzzi L, Kepp O et al (2011) Oncosuppressive functions of autophagy. Antioxid Redox Signal 14:2251–2269CrossRefPubMed
30.
Kondo Y, Kanzawa T, Sawaya R et al (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734CrossRefPubMed
31.
Kim K, Moretti L, Lu B (2008) Combined Bcl(2)/mTOR inhibition leads to enhanced radiosensitization via induction of autophagy and apoptosis in non-small lung tumor xenograft model. Int J Radiat Oncol 72:S45CrossRef
32.
Amaravadi RK, Yu D, Lum JJ et al (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Investig 117:326–336CrossRefPubMedPubMedCentral
33.
Poole B, Ohkuma S (1981) Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 90:665–669CrossRefPubMed
34.
Solomon VR, Lee H (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625:220–233CrossRefPubMed
35.
36.
37.
38.
Dragowska WH, Weppler SA, Wang JC et al (2013) Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS ONE 8(10):e76503CrossRefPubMedPubMedCentral
39.
Cook KL, Wärri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Clarke R (2014) Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res 20(12):3222–3232CrossRefPubMedPubMedCentral
40.
Helgason GV, Mukhopadhyay A, Karvela M et al (2013) Autophagy in Chronic Myeloid Leukaemia: stem Cell Survival and Implication in Therapy. Curr Cancer Drug Targets 13:724–734CrossRefPubMed
41.
Pan Y, Gao Y, Chen L et al (2011) Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Can Res 17:3248–3258CrossRef
42.
43.
Li J, Yang B, Zhou Q et al (2013) Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis 34:1343–1351CrossRefPubMed
44.
Yang A, Kimmelman AC (2014) Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status. Autophagy 10(9):1683–1684CrossRefPubMedPubMedCentral
45.
Carew JS, Nawrocki ST, Kahue CN et al (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110:313–322CrossRefPubMedPubMedCentral
46.
Carew JS, Medina EC, Esquivel JA et al (2010) Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 14:2448–2459CrossRefPubMed
47.
Ma XH, Piao S, Wang D et al (2011) Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 17:3478–3489CrossRefPubMedPubMedCentral
48.
Kawaguchi T, Miyazawa K, Moriya S et al (2011) Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol 38:643–654PubMed
49.
Shen JPYC, Divakaran S, Bradner JE et al (2008) The rationale for combined proteasome and autophagy inhibition in multiple myeloma established using novel translational platforms. Am Soc Hematol 112:2755
50.
Escalante AM, McGrath RT, Karolak MR et al (2013) Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol 71:1567–1576CrossRefPubMedPubMedCentral
51.
Poklepovic A, Gewirtz DA (2014) Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. Autophagy 10:1478–1480CrossRefPubMedPubMedCentral
52.
Gewirtz David A (2014) The autophagic response to radiation: relevance for radiation sensitization in cancer therapy. Radiat Res Soc 182(4):363–367CrossRef
53.
Easterbrook M (1992) Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 27:237–239PubMed
54.
Elman A, Gullberg R, Nilsson E et al (1976) Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol 5:161–166CrossRefPubMed
55.
Levy GD, Munz SJ, Paschal J et al (1997) Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 40(8):1482–1486CrossRefPubMed
56.
Mavrikakis I, Sfikakis PP, Mavrikakis E et al (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 110(7):1321–1326CrossRefPubMed
57.
Furst DE, Lindsley H, Baethge B et al (1999) Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 42(2):357–365CrossRefPubMed
58.
Munster T, Gibbs JP, Shen D et al (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46(6):1460–1469CrossRefPubMed
59.
Leung LS, Neal JW, Wakelee HA et al (2015) Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 160:799–805CrossRefPubMed
60.
Nika M, Blachley TS, Edwards P et al (2014) Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol 132(10):1199–1208CrossRefPubMedPubMedCentral
61.
Marmor MF (2012) Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 130(4):461–469CrossRefPubMed
62.
McAfee Q, Zhang Z, Samanta A et al (2012) Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 109:8253–8258CrossRefPubMedPubMedCentral
63.
Bristol ML, Emery SM, Maycotte P et al (2013) Autophagy inhibition for chemosensitization and radiosensitization in cancer: Do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 344:544–552CrossRefPubMedPubMedCentral
64.
Gallagher FA, Kettunen MI, Day SE et al (2008) Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453(7197):940–943CrossRefPubMed
65.
De Milito A, Canese R, Marino ML et al (2009) pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 127:207–219CrossRef
66.
Robey IF, Baggett BK, Kirkpatrick ND et al (2009) Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 69(6):2260–2268CrossRefPubMedPubMedCentral
67.
Pellegrini P, Strambi A, Zipoli C et al (2014) Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies. Autophagy 10(4):562–571CrossRefPubMedPubMedCentral
68.
69.
Ma XH, Piao SF, Dey S et al (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Investig 124:1406–1417CrossRefPubMedPubMedCentral
70.
Ronan B, Flamand O, Vescovi L et al (2014) A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 10(12):1013–1019CrossRefPubMed
71.
Pasquier B (2015) SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with mTOR inhibition in tumor cells. Autophagy 4:725–726CrossRef
72.
Donohue E, Tovey A, Vogl AW et al (2011) Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem 286:72CrossRef
73.
Donohue E, Thomas A, Maurer N et al (2013) The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer 4(7):585–596CrossRefPubMedPubMedCentral
74.
Goodall ML, Wang T, Martin KR et al (2014) Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib. Autophagy 10:1120–1136CrossRefPubMedPubMedCentral
75.
Sharma N, Thomas S, Golden EB et al (2012) Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett 326(2):143–154CrossRefPubMed
76.
Liu J, Xia H, Kim M et al (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147(1):223–234CrossRefPubMedPubMedCentral
77.
Chloroquine and its analogs (2009) A new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625(1–3):220–233
Metadaten
Titel
Research progress of hydroxychloroquine and autophagy inhibitors on cancer
verfasst von
Ting-Ting Shi
Xiao-Xu Yu
Li-Jun Yan
Hong-Tao Xiao
Publikationsdatum
26.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3197-1

Weitere Artikel der Ausgabe 2/2017

Cancer Chemotherapy and Pharmacology 2/2017 Zur Ausgabe

Original Article

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

Original Article

Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents

Review Article

Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells

Original Article

The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy

Review Article

Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors

Original Article

Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise